Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

NCT04561076 | Withdrawn Phase 1 DMC FDA Drug

• 1 other identifier: HLX70-001US-255086
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

Conditions

COVID 19

Outcome Measures

Primary Outcomes (2)

• Number of participants with adverse events, serious adverse event and infusion-related reactions as assessed by CTCAE v5.0

  up to 92 days

• Safety evaluation- proportion of subjects undergoing DLT events

  The proportion of subjects undergoing DLT events

  Days 1 to 7

Secondary Outcomes (9)

• PK parameters-Areas under the concentration-time curves

  pre-infusion (pre-dose), immediately post-infusion, 3 hours, 6 hours and 10 hours post-infusion, Days 2, 3, 5, 8, 11, 15, 22, 29, 43, 57, 71 and 92.

• PK parameters-Maximum measured concentration

  pre-infusion (pre-dose), immediately post-infusion, 3 hours, 6 hours and 10 hours post-infusion, Days 2, 3, 5, 8, 11, 15, 22, 29, 43, 57, 71 and 92.

• PK parameters-Time from dosing to maximum measured concentration

  pre-infusion (pre-dose), immediately post-infusion, 3 hours, 6 hours and 10 hours post-infusion, Days 2, 3, 5, 8, 11, 15, 22, 29, 43, 57, 71 and 92.

• PK parameters-Terminal phase elimination rate constant

  pre-infusion (pre-dose), immediately post-infusion, 3 hours, 6 hours and 10 hours post-infusion, Days 2, 3, 5, 8, 11, 15, 22, 29, 43, 57, 71 and 92.

• PK parameters-Terminal phase elimination half life

  pre-infusion (pre-dose), immediately post-infusion, 3 hours, 6 hours and 10 hours post-infusion, Days 2, 3, 5, 8, 11, 15, 22, 29, 43, 57, 71 and 92.

Study Arms (3)

Sequence 1

EXPERIMENTAL

Random allocation to HLX70 3 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.

Drug: HLX70; Other: Placebo

Sequence 2

EXPERIMENTAL

Random allocation to HLX70 10 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.

Drug: HLX70; Other: Placebo

Sequence 3

EXPERIMENTAL

Random allocation to HLX70 30 mg/kg (IV, single dose), or placebo (IV, single dose) of which 2 receive intravenous injections of placebo and 6 receive intravenous injections of the HLX70.

Drug: HLX70; Other: Placebo

Interventions

HLX70 DRUG

Single-dose, intravenous infusion

Also known as: Anti-spike protein-1 monoclonal antibody (mAb)

Sequence 1; Sequence 2; Sequence 3

Placebo OTHER

Single-dose, intravenous infusion

Sequence 1; Sequence 2; Sequence 3

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects with voluntary signing of the informed consent form (ICF);
• Healthy males or females aged ≥ 18 and ≤ 60 years at the time of signing the ICF;
• Subjects with body weight ≥ 50 kg and body mass index (BMI) must be higher than 18.5 kg/m2 and lower than 30 kg/m2 at screening visit;
• Subjects who are determined to be in good health according to medical history, normal (site normal ranges to be followed) or abnormal but clinically insignificant physical examination, vital signs, ECG, laboratory test results (including hematology, serum chemistry, coagulation function, urinalysis, etc.), and investigator's clinical judgment (CTCAE grade 1 of triglycerides and uric acid is permitted). One re-test allowed per investigator discretion to confirm result.
• Subject who agrees that he/she, and his/her spouse or partner, will use reliable contraception (see appendix 1) for 9 months after administration.

You may not qualify if:

• Subjects with the lab-confirmed medical history of COVID-19, including nucleic acid (PCR testing of nasopharyngeal samples) tested positive or antibody IgG/IgM tested positive.
• Subjects with the novel onset of pyrexia/cough/shortness of breath/diarrhea or history of contact with confirmed COVID-19 individuals (positive for SARS-CoV-2 nucleic acid) within the 14 days before randomization.
• Subjects who are known to have chronic obstructive pulmonary disease (COPD), cirrhosis of liver, cardiac failure or any condition that requires active medical intervention or monitoring to avert serious danger to the participant's health or well-being.
• Subjects with pneumonia or tuberculosis (TB) suggested by chest X-Ray.
• Subjects with previous exposure to a mAb or any other biological agents in 6 months before screening.
• Subjects with previous exposure to vaccines in 3 months before screening, or who plans to receive vaccination during the study period or in 3 months after the study.
• Subjects with previous participation in clinical trials receiving investigational drug/comparator within the longer of 30 days or 5 half-lives before screening.
• Subjects who are known to have a history of allergy to any mAb, biological product, protein product, or the ingredient of the IP.
• Subjects with positive test result(s) for hepatitis B virus (positive for HBsAg or positive for HBcAb and HBV-DNA), hepatitis C virus (HCV) antibodies, human immunodeficiency virus (HIV) antibodies, or treponema pallidum.
• Subjects who are known to have a history of psychotropic drug abuse, alcoholism, or drug addiction within the last year.

Sponsors & Collaborators

• Hengenix Biotech Inc: lead
• Sanyou Biopharmaceuticals(Shanghai)Co., Ltd: collaborator
• Shanghai ZJ Bio-Tech Co., Ltd: collaborator

Related Publications (1)

• Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

  PMID: 34473343 DERIVED

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Esther Yoon, MD

  California Clinical Trials Medical Group (CCTMG) managed by Parexel

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Double-Blind, Placebo-Controlled
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 7, 2020
• First Posted: September 23, 2020
• Study Start: December 9, 2020
• Primary Completion: September 6, 2021
• Study Completion: September 18, 2021
• Last Updated: April 1, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share